Posters

Enhanced-fluence pulsed-light iontophoresis corneal cross-linking (EF I-CXL): 1 year morphological and clinical results

Poster Details

First Author: C.Mazzotta ITALY

Co Author(s):                        

Abstract Details

Purpose:

To assess safety and efficacy of a novel Pulsed-Light Enhanced-Fluence Iontophoresis corneal collagen Cross Linking (EF I-CXL) in patients with progressive Keratoconus (KC).

Setting:

Siena Crosslinking Center, Siena, Italy

Methods:

Prospective interventional pilot study including 12 eyes of 10 patients, 80% male, mean age 24.8 years (range 15-36 y). Iontophoresis with the Ricrolin+® solution was used for stromal imbibition. The treatment Energy Dose (Fluence) was optimized at 30% (from 5.4J to 7J/cm2) and UV-A power set at 18mW/cm2 x 6.28 min of exposure time, pulsing the light 1 sec on/ 1 sec off with a total irradiation time of 12.56 min. Uncorrected distance visual acuity (UDVA), Corrected Distance Visual Acuity (CDVA), Scheimpflug Corneal Tomography data and Corneal OCT at baseline, 1,3,6,12-months were evaluated.

Results:

Twelve-month statistically significant average data (p <0.05) showed UDVA decrease from 0.50 ± 0.10 to 0.36 ± 0.08 LogMAR, K max reduction from 52.86 ± 1.5 D to 51.49 ±0.9 D, SAI decrease from 2.34±0.36 to 2.13±1.12 D, SI diminution from 4.22±1.01 to 3.56±0.90 D, Coma reduction from 0.25±0.05 to 0.14 ±0.06µm. Corneal OCT showed an over 80% demarcation line detection at 295.8 ±20.2 µm depth on average in the 1st postop month.

Conclusions:

The preliminary results of EF I-CXL protocol demonstrate its capability to rise I-CXL efficacy through increased demarcation line visibility, repeatability and depth, K max reduction closer to S-CXL by enhancing the UV-A Fluence and pulsing the UV-light thus compensating epithelium UV-A absorbance and oxygen consumption.

Financial Disclosure:

None